SCHEMBL4140451

SCHEMBL4140451

CCCC(C(=O)O)c1ccc(NC2=NC(=O)C(=Cc3ccc(-c4cc(CO)c(O)c(OC)c4)cc3)S2)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 11/20 0.36
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
MAPT P10636 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 4/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
PSMD14 O00487 2/20 0.36
LMNA P02545 2/20 0.36
MMP2 P08253 1/20 0.36
G6PD P11413 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 2/20 0.36
PTPN1 P18031 3/20 0.35
HKDC1 Q2TB90 1/20 0.33
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
MITF O75030 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140448 1.00 ALOX5 (0.36) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4128315 0.82 KMT2A (0.37) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4128320 0.82 KMT2A (0.37) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4141062 0.80 PTPN1 (0.42) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4141057 0.80 PTPN1 (0.42) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4134054 0.79 ALOX5 (0.37) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4134057 0.79 ALOX5 (0.37) ALOX5KMT2AMEN1MAPTALDH1A1
SCHEMBL4129615 0.75 ALOX5 (0.48) ALOX5
SCHEMBL4129611 0.75 ALOX5 (0.48) ALOX5
SCHEMBL4133852 0.75 PRMT5 (0.46) ALOX5KMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885KMT2A 2895/4885MEN1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.